Most pharma firms bring in consultants as a reaction to a particular situation. There has been an inspection, and a deficiency has been found. There is a warning letter received. There has been a customer audit that reveals certain patterns of deviations which had gone unnoticed. Hence, the consulting project is a remediation effort, and remediation is a different ballgame from prevention.

Proactive GMP compliance consulting by firms such as Pharmazones, a trusted integrated GxP & Regulatory Consulting firm globally, can flip the sequence of events. This reflects in scope, in timing, and in practical impact of the project.

Prevention of GMP Compliance Issues Is a Different Animal Altogether

This is not a criticism of the quality department’s functioning. The budget is approved when there is a known problem and prevention efforts compete with production priorities. Support is brought in reactively since that is the time when it becomes clear. The cost of the approach remains hidden until later, and it is becoming evident now for the Indian manufacturers.

Schedule M Has Changed from a Deadline to an Enforcement Directive

The Revised Schedule M was notified in December 2023 under G.S.R. 922(E) and became applicable to large manufacturers from June 2024. The GMP requirements in India have thus become closer to WHO and PIC/S requirements. Manufacturers below the ₹250 crore turnover threshold were given an extension option under G.S.R. 127(E) of February 2025, which put the compliance date at 1 January 2026 for those who applied. That date has now passed.

The important aspect of it is how few have taken advantage of it. Most eligible MSME units never sought an extension at all. The directive of 7 November 2025 from the DCGI instructed state licensing authorities to conduct inspections under revised Schedule M right away at all such manufacturers, and to plan inspections at those that sought it “to verify their compliance with the requirements.” The state drug controllers have also been requested to submit monthly reports to CDSCO on the inspection findings, observations and actions taken.

The point is the change in the reporting requirement. Inspection is no longer only a sporadic activity triggered by a complaint or an upcoming planned inspection. With monthly reports going to CDSCO, findings are now tracked centrally, in addition to the general oversight of the quality of manufacturing, which has been intensified after the cough syrup contamination incidents in late 2025.

The issue facing any Indian manufacturer now is not whether there will be an inspection and when. The issue is what it will find. A pre-inspection gap assessment of Schedule M conducted before the inspection will reveal it privately. The inspection will reveal it publicly.

Whether you sought an extension or not, the revised requirements now apply to your unit, and an independent pre-inspection gap assessment against them is the next step. Get in touch with our team for timely and routine audits.

The Most Common Observation Has a Structural Nature

Manufacturers exporting their products into regulated markets face a similar issue under a different set of rules. According to the FDA’s published observation data for drug facilities, one of the most frequently observed issues over several consecutive years is 21 CFR 211.22(d), covering responsibilities and procedures of the quality control unit.

The issue in question is not contamination of any particular batch or failure of the stability study. The issue in question is whether the quality control unit has the procedures and whether they are being adhered to. The observation in question is not about what was manufactured recently, but about how the organization works. Schedule M is raising the same underlying issue about the quality management system. Hence, upgrades limited to premises and equipment fail to address the problem.

Structural Limitations of the Reactive Approach

Each reactive engagement addresses the problem for which it has been commissioned. What it does not do is review the underlying systems, and that is due to the limited scope that was necessary.

After some such cycles, a firm ends up with a patchwork of individual solutions rather than with a quality strategy. A CAPA addresses one deviation. A response letter addresses one observation. Supplier issues are sorted out with one vendor. Each of them is good on its own, but none of them questions whether there is anything wrong with the structure. How many of your last 5 engagements have started with finding rather than planning?

Independent GMP audit services conducted without the pressure of an active observation give an opportunity to look beyond one identified problem and to detect any patterns while there is still time to address the cause rather than the symptom.

What Proactive GMP Compliance Consulting Looks Like

The proactive approach involves a series of periodic reviews of the systems, rather than one deep dive audit. It involves continuous monitoring of the CAPA effectiveness, rather than a one-time closure check. It involves continuous supplier monitoring rather than annual questionnaires. It involves maintaining a partner who is well aware of your operation to detect deviations early on.

The pre-inspection gap assessment or a scheduled GxP audit will look through the same documents, the same investigation records, the same data governance controls that will be examined by a state drug inspector or by an overseas inspector. The difference is the clock. The issues you have identified yourself can be addressed without an external deadline to respond to. That is why audits and inspection readiness work better as a continuous process rather than as a project tied to a scheduled visit.

None of the above requires an existing problem as a reason to implement it. It requires recognizing that discovery of the problem during inspection is much more costly, in terms of time, resources, and regulatory standing, than discovering the same problem during a review that you have scheduled yourself.

Working on Your Schedule, Not Someone Else’s

Reactive consulting can do good work too. It closes the problem and helps you get back on track. However, it runs on a schedule set by someone else.

Proactive GMP compliance consulting done in advance gives you a much broader scope and freedom to examine the whole system rather than just the broken part. The difference accumulates over the years of your operation.

For related reading, see our article about the mistake almost every pharmaceutical facility makes when preparing for inspection.

To go from reactive fixes to a sustainable compliance strategy. Contact the Pharmazone Team to schedule a system review.